In yesterday’s Wall Street session, Plus Therapeutics Inc. (NASDAQ:PSTV) shares traded at $0.30, down -7.75% from the previous session.
4 analysts cover Plus Therapeutics Inc. (NASDAQ:PSTV), according to research data. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $5.00 and a low of $2.00, we find $4.25. Given the previous closing price of $0.33, this indicates a potential upside of 1187.88 percent. PSTV stock price is now -21.37% away from the 50-day moving average and -39.16% away from the 200-day moving average. The market capitalization of the company currently stands at $10.00M.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
The stock has received a hold rating from 0 analysts and a buy rating from 4. Brokers who have rated the stock have averaged $3.88 as their price target over the next twelve months.
With the price target of $8, Ladenburg Thalmann recently initiated with Buy rating for Plus Therapeutics Inc. (NASDAQ: PSTV). On October 16, 2020, Maxim Group recently initiated its ‘Buy’ rating on the stock quoting a target price of $6.
In other news, Hawkins Richard J, Director bought 1 shares of the company’s stock on Mar 03. The stock was bought for $1 at an average price of $1.00. Upon completion of the transaction, the Director now directly owns 1 shares in the company, valued at $0.3. An SEC document containing details of the transaction can be found on the SEC’s website. On Dec 30, Director Lenk Robert P sold 1,500 shares of the business’s stock. A total of $472 was realized by selling the stock at an average price of $0.31. This leaves the insider owning 8,500 shares of the company worth $2550.0. Insiders disposed of 1,500 shares of company stock worth roughly $450.0 over the past 1 year. A total of 0.39% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in PSTV stock. A new stake in Plus Therapeutics Inc. shares was purchased by SCHONFELD STRATEGIC ADVISORS LLC during the first quarter worth $62,000. B. RILEY WEALTH ADVISORS, INC. invested $8,000 in shares of PSTV during the first quarter. In the first quarter, VIRTU FINANCIAL LLC acquired a new stake in Plus Therapeutics Inc. valued at approximately $4,000. TWO SIGMA INVESTMENTS, LP acquired a new stake in PSTV for approximately $3,000. In total, there are 26 active investors with 10.50% ownership of the company’s stock.
On Wednesday morning Plus Therapeutics Inc. (NASDAQ: PSTV) stock kicked off with the opening price of $0.3100. During the past 12 months, Plus Therapeutics Inc. has had a low of $0.29 and a high of $1.20. As of last week, the company has a debt-to-equity ratio of 0.84, a current ratio of 1.80, and a quick ratio of 1.80. The fifty day moving average price for PSTV is $0.3816 and a two-hundred day moving average price translates $0.4924 for the stock.
The latest earnings results from Plus Therapeutics Inc. (NASDAQ: PSTV) was released for Sep, 2022. According to the Biotechnology Company, earnings per share came in at -$0.19, beating analysts’ expectations of -$0.2 by 0.01. This compares to -$0.25 EPS in the same period last year. For the current quarter, analysts expect PSTV to generate $1.27M in revenue.
Plus Therapeutics Inc.(PSTV) Company Profile
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx’s glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
